QuintilesIMS analysts forecast a wave of new drug approvals by '22, dominated by cancer and orphan therapies
To hear analysts at the QuintilesIMS Institute tell it, 2016’s sudden plunge in new drug approvals was an aberration that won’t be repeated anytime over the next five years. In their new, annual drug spending report, the analysts at this group determined that the industry pipeline is brimming full and likely to spew out 40 to 45 new drug approvals every year from this year through 2022, returning to a level set in 2014 and 2015.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
